Director-level Biostatistician with extensive industry experience leading statistical strategy for global clinical development programs across all phases (Phases 1–4). Offers deep hands-on expertise in regulatory submissions and strategic interactions with the FDA, EMA, Health Canada, PMDA, and TGA. Recognized for cross-functional collaboration and translating complex statistical data into actionable, evidence-based decisions that accelerate development and support successful commercialization.
Kyverna Therapeutics • June 2025 – February 2026
Led biostatistical strategy and built department standards for global clinical programs.
Atara Biotherapeutics • March 2024 – March 2025
Atara Biotherapeutics • March 2022 – March 2024
Full detailed experience available in the downloadable CV.